INTRODUCTION
Over the past decade, aberrations in genes coding for G-protein activating subunits have been increasingly implicated in tumorigenesis.
1 G-protein activating subunits, such as those encoded by the genes GNAS, GNAQ, GNA11 and GNA12, bind to G protein-coupled receptors (GPCRs) and play central roles in cellular signaling transduction.
2,3 G-proteins and GPCRs are ubiquitously expressed and are critical throughout transcription, cell division, motility, and secretion. Specifically, the GNAS locus encodes the alpha subunit of the stimulatory G protein (Gα s ), which activates a cAMP dependent pathway to regulate the actions of hormones, neurotransmitters, and other paracrine/autocrine signaling cascades. 4 In addition to the recognized role of GNAS aberrations in hereditary endocrinopathies including pseudohypoparathyroidism and Albright syndrome, [4] [5] [6] the role of GNA aberrations as driver mutations in diverse tumors has become clearer. 1, 7 The advent of next-generation sequencing has unearthed diverse genomic aberrations that are associated with different cancer types. [8] [9] [10] [11] [12] Specifically, recent deep sequencing analysis has revealed that 4.4% of tumors carry GNAS aberrations. 1 Several studies have shown that GNAS aberrations span a wide variety of endocrine tumors, including those originating from the pituitary (28%), pancreas (12%), thyroid (5%), and parathyroid (3%), ovary (3%), endometrium (2%). 1 However, more recent reports have demonstrated that the protumorigenic effect of these mutations is not limited
Cancer October 15, 2018 to endocrine lesions; GNAS aberrations are also harbored by intramuscular myxomas, fibrous dysplasias, colorectal cancers, appendiceal mucinous tumors, hepatocellular carcinoma, and both mucinous and nonmucinous lung adenocarcinomas. [13] [14] [15] [16] [17] One potential mechanism by which gain-of-function mutations in GNAS can lead to carcinogenesis is the regulation of inflammatory mediators such as cyclooxygenase-2 (COX-2) derived prostaglandins by Gα s . 15 It is possible that these mutations can lead to an autonomous proinflammatory state, which promotes tumorigenesis. This is particularly likely in the setting of colon cancer, which has been previously linked to COX-2 overexpression. [18] [19] [20] Likewise, GNAQ/GNA11 (Gα q ) mutations are harbored by 5.6% of tumors. For example, activating mutations of GNAQ/GNA11 are present in 66% and 6% of melanomas arising in the eye and skin, respectively. 20 Moreover, GNAQ/GNA11 has been implicated as the driver oncogene in uveal melanoma. 21 Other studies have found GNAQ mutations in 83% of blue nevi and 59% of tumors arising from the meninges. 22, 23 Despite the presence of GNAQ family alterations in benign lesions such as blue nevi, these alterations are believed to drive tumorigenesis, a phenomenon noted with other driver oncogenes as well. 24, 25 Advances in deep sequencing technology have unearthed a previously unappreciated widespread, protumorigenic role of G protein α subunits, particularly those encoded by GNAS and GNAQ/GNA11, in a diverse collection of malignancies. 1 The aim of this study was to determine the GNAS/GNAQ/GNA11 aberration status among a cohort of 1348 cancer patients, and to compare mutational burden, co-alteration status, overall survival rates, and treatment outcomes between GNA* positive versus GNA* wild-type patients.
MATERIALS AND METHODS

Patients
In total, 1348 patients with genomic data were included. For each patient, a variety of clinical and demographic data was obtained, as well as a variety of molecular information from their tumor samples, including gene, type of aberration (amplification, frameshift, missense/ nonsense mutation, etc.), and whether the variant was of known or unknown significance. All data was derived from medical records as part of the UC San Diego Profile Related Evidence Determining Individualized Cancer Therapy (PREDICT) study (NCT02478931), which was performed in accordance with UCSD IRB guidelines.
Molecular Data
Next-generation sequencing (NGS) for each patient was performed by Foundation Medicine (FoundationOne; https://www.foundationone.com). For the included patients, the used gene panels varied from 182 to 236, but all panels included GNAS, GNAQ and GNA11. The test is a clinical-grade, clinical laboratory improvement Amendments (CLIA) approved NGS test. Typical median depth of coverage is greater than 500X. This test can detect base substitutions, insertions and deletions (indels), copy number alterations (CNAs) and rearrangements using a routine tissue sample (including core or fine needle biopsies).
Tumor mutational burden (TMB) was estimated for each patient using a validated algorithm: the number of somatic mutations detected on NGS (inter-rogating 1.2 mb of the genome) are quantified, and that value is then extrapolated to the entire exome. 26, 27 Alterations likely or known to be bona fide oncogenic drivers and germline polymorphisms are excluded. TMB was measured in total mutations per megabase (mb). 26 Variants of unknown significance (VUS) were excluded from all analyses except for TMB.
Statistical Analysis
All statistical processing was performed using the R Statistical Programming Language. 21, 28 For comparisons between continuous values, the Wilcoxon rank sum test was used; for comparing frequencies, the 2-sided Fisher exact test was used. Haldane's correction was applied whenever count data equaled zero. 29 Statistical significance was taken to occur at the alpha = 0.05 level.
Outcomes
Overall survival was calculated by the method of Kaplan and Meier, starting from the date of diagnosis. Data were censored at the date of last follow-up for patients who were still alive. Differences between survival curves were assessed using the log-rank test as well as the Cox proportional hazards method.
RESULTS
Patient Characteristics
Thirteen hundred forty-8 patients were analyzed, 630 of whom (46.7%) were male. The median age of the patients was 56.1 years (range 1.0 to 95.1 years). The most common diagnoses were brain (167 of 1348, 12.4%), breast (155 of 1348, 11.5%), lung (143 of 1348, 10.6%) and gastrointestinal cancers excluding appendiceal and colorectal (134 of 1348, 9.9%). Of all 1348 patients, 55
Cancer October 15, 2018 had GNAS, GNAQ or GNA11 aberrations (4.1%). There was no association between age, gender, or ethnicity and GNA* aberrations. Overall, in univariate analysis, GNA* aberrations correlated with peritoneal metastases (OR = 2.8, 1.2 to 6.0, P = .012) and both appendiceal (OR = 9.9, 4.7 to 20.8, P<.0001) and ocular melanoma diagnoses (OR = 75.0, 7.6 to 729.0, P = .0003). These observations are in line with previous results. 21, 22, 30, 31 In addition, we found GNA* aberrations to be associated with fewer brain tumor diagnoses (OR = 0.06 with Haldane's correction, 0.004 to 1.0, P = .0012). These results are summarized in Table 1 . Analyzing pathologic and tissue molecular characteristics, we found GNAS/GNAQ/GNA11 aberrations to be significantly associated with adenocarcinoma histology (OR = 2.0, 1.0 to 3.8, P = .037), as summarized in Table 2 . Abbreviations: CI, confidence interval; CNS, central nervous system; GNA*, guanine nucleotide-binding (G) protein α (GNA) subunits; GNA11, GNA subunit 11; GNAS, GNA Gs subunit; GNAQ, GNA Gq subunit; KM, Kaplan-Meier; NA, not available; OR, odds ratio; OS, overall survival; PFS, progression-free survival. a Aberrations refer to characterized alterations, and "GNA*" refers to GNAS, GNAQ, or GNA11 aberrations. 
Molecular Landscape of Patients With GNA* Alterations
Patients with GNA* aberrant tumors also had an increased number of aberrations overall, an association which remained after excluding VUSs and excluding GNA* aberrations from the total count (P = .0028 for this final comparison). In univariate analysis of the coaberration network, of the 35 most frequent mutations, a total of 8 aberrations were significantly associated with GNA* aberrations at the alpha = 0.05 level: KRAS, MYC, AURKA, SRC, TOP1, AKT2, CBL and LYN. These results are summarized in Table 2 . In total, 271 independent aberrations that occurred in 2 or more patients were identified from the data. The frequency of the aberrations followed a power law distribution with scaling parameter alpha = 1.55 (1.51 to 1.59). For each unique aberration, we tested the hypothesis whether there were more co-alterations overall in patients with that aberration than in patients without that aberration. We excluded variants of unknown significance and we did not count the index aberration in the total number. We found that a total of 105 of 271 (38.7%) are significant at P≤.05; using the Bonferroni correction 32 for multiple comparisons, a total of 31 of 271 (11.4%) are significant at P≤.00,018.
In addition, we checked to see whether frequency of an aberration was related to odds of being significant, with correction for multiple comparisons. A logistic regression model was run with (significant) (frequency), yielding an odds ratio of 1.013 (1.005 to 1.022, P = .0014). Thus, increased frequency of an aberration was associated with a greater tendency for that aberration to be associated with a higher number of co-alterations. Rare aberrations therefore do not seem uniquely associated with higher total number of co-alterations.
Multivariate Analysis of Covariates Associated With GNA* Alterations
Characteristics independently associated with
GNA* alterations
To test the stability of these associations, we ran a multivariable logistic regression model of GNAS/GNAQ/GNA11 aberration status versus all features that were found in univariate analysis to be associated with GNA* at P≤.1. From the results above, this included 18 variables: adenocarcinoma histology, peritoneal metastasis, brain cancer diagnosis, ocular melanoma diagnosis, appendiceal cancer diagnosis, number of characterized genomic co-alterations, and aberrations in KRAS, MYC, SMAD4, AURKA, MCL1, SRC, TOP1, CCNE1, AKT2, CBL, LYN and ZNF703. Of these features, ocular melanoma diagnosis, appendiceal histology, and KRAS, AURKA, SRC, CBL and LYN aberrations were significantly associated with GNA* aberrations at the alpha = 0.05 level as shown in Table 3 .
At the Bonferroni corrected p-value cutoff of 0.05 of 18 = 0.0028, KRAS is no longer significantly associated with GNA*, but the other features (ocular melanoma, appendiceal cancer, AURKA, SRC, CBL and LYN) remain significantly associated, in alignment with previous reports. 13, 26, 30, 33, 34 The diagnosis of ocular melanoma is particularly strongly associated (OR = 2.09, P<.0001) which is consistent with previous literature findings. 21, 22, 31 Treatment regimens and GNA* alterations By using the longest measured (best) progression free survival as an outcome, we ran a Cox proportional hazards model of PFS versus treatment for various treatment regimens, including VEGF inhibitors, taxanes, capecitabine/ gemcitabine, platins and hormonal agents. Given the very small numbers of patients with GNA* aberrations who also had a best PFS measured for these regimens (all n ≤11), no therapy was found to be significantly associated with PFS. These results are summarized in Supplemental Table 1 .
We also examined whether any patients had exceptional responses after therapy for metastatic disease. Of the 43 patients with GNA* alterations who developed metastatic disease, PFS data on systemic treatment was available for 24 of them. Of these 24 patients, 4 had a PFS of over 1.5 years (16.7%); they were treated with the following regimens: tamoxifen, exemestane, letrozole (all breast cancer), and CyBorD (cyclophosphamide, bortezomib, dexamethasone) (multiple myeloma). These drugs are not implicated in the GNA* pathway and it is likely that the responses are unrelated. Figure 1 shows the overall aberrational landscape for the 55 GNAS/GNAQ/GNA11 aberrant patients, including associated tumor diagnoses and the top 40 most frequent genomic co-alterations. ZNF217, AURKA, TP53, KRAS, MYC, SMAD4 and cyclin aberrations were frequently found, but as found with the multivariate model above only AURKA, SRC, CBL and LYN remained uniquely and significantly associated with GNA* aberrations in our patient population. The AURKA association is both frequent (17 of 55, 31.0%) and significantly associated with GNA* aberrations. Abbreviations: AKT2, AKT serine/threonine kinase 2; AURKA, Aurora kinase A; CBL, Cbl proto-oncogene; CCNE1, cyclin E1; CI, confidence interval; GNA*, guanine nucleotide-binding (G) protein α (GNA) subunits; GNA11, GNA subunit 11; GNAS, GNA Gs subunit; GNAQ, GNA Gq subunit; KRAS, Kirsten rat sarcoma oncogene, guanosine triphosphatase; LYN, LYN proto-oncogene, Src family tyrosine kinase; MCL1, myeloid cell leukemia 1; MYC, v-myc avian myelocytomatosis viral oncogene homolog; OR, odds ratio; SMAD4, SMAD family member 4; SRC, SRC proto-oncogene, nonreceptor tyrosine kinase; TOP1, DNA topoisomerase 1; ZNF703, zinc finger protein 703. a All of the following variables were associated (at P ≤ .1) with GNAS in a univariate model (Fisher exact test) (see Tables 1 and 2 ) and were included in a multivariate logistic regression model: adenocarcinoma histology, peritoneal metastasis, brain cancer diagnosis, ocular melanoma diagnosis, appendiceal cancer diagnosis, number of characterized genomic co-alterations, KRAS, MYC, SMAD4, AURKA, MCL1, SRC, TOP1, CCNE1, AKT2, CBL, LYN, and ZNF703. In the multivariate model, results were considered significant if P ≤ .05. b Because all 18 factors with P values ≤ .1 in univariate were included, the Bonferroni correction was used to account for multiple comparisons. A significant P value after Bonferroni correction was ≤ .0028. These P values indicate statistical significance at the α = .05 level.
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Cancer October 15, 2018 survival, (median OS 26.3 vs 35.2 months), the difference is not statistically significant (log-rank P = .085).
DISCUSSION
Aberrations in genes coding for G-protein activating subunits have been increasingly implicated in the tumorigenesis of a variety of cancers, including those of endocrine, gastrointestinal, cutaneous, and ocular origin. The advent of deep sequencing technology has elucidated the protumorigenic role of various GNA* (GNAS, GNAQ, GNA11) aberrations in a diverse array of malignancies. Thus, the aim of the present study was to determine the spectrum of GNAS/GNAQ/GNA11 aberrations across a cohort of 1348 cancer patients, and to compare mutational burden, overall survival rates, and treatment outcomes between GNA* positive versus GNA* wild-type patients. Consistent with previous reports, our multivariate analysis highlights a significant association between GNA* aberrations and appendiceal cancer (OR = 2.09, P<.0001). A possible explanation for this correlation is that mutant GNAS may disrupt the cAMP-dependent signaling pathway that induces mucin gene expression, which is the hallmark of these tumors. 13 Likewise, we also demonstrated a significant association between positive GNA* aberration status and ocular melanoma diagnoses (OR = 2.09, P<.0001). One likely explanation for this association is the implication of GNAQ in endothelin signaling, which is central to melanocyte survival during early development. 22, 35 We found that the higher the frequency of an alteration, the more likely it was to be accompanied by co-alterations. Even so, GNA* aberrations, which were found in 4.1% of our population, frequently co-occurred with higher numbers of co-alterations as well as with several specific aberrations including KRAS, AURKA, SRC, CBL and LYN, which also affect critical oncogenic pathways. These co-alterations have important therapeutic implications, as they may guide the development of novel drug combinations that dually target these genetic pathways.
Although individuals with GNA*-aberrant tumors had lower overall survival rates than patients with wildtype tumors (median survival of 26.3 vs 35.2 months from diagnosis), this difference showed only a trend toward statistical significance (log-rank P = .085). The calculations may have been limited by the small number of GNA*-positive relative to GNA*-negative patients. (n = 55 vs n = 1293). Thus, future studies with a larger sample size of patients with GNA* aberrations may provide more insight into the prognostic implications of these Overall Survival According to GNAS/GNAQ/GNA11 Status
Cancer October 15, 2018 mutations. We also did not find a relationship between PFS and GNA* status for a variety of treatment regimens, including VEGF inhibitors, taxanes, capecitabine/gemcitabine, platins and hormonal agents, but small samples size precluded robust statistical analysis. There are several limitations to the study, including its retrospective nature and the finding that germline controls were not used to assess the molecular characteristics. However, in regard to the latter, the NGS assay is nonetheless well validated and now approved by the Food and Drug Administration. Another limitation of the study was that the proportion of different histologies tested was influenced by referral patterns to our institution and the adoption of genomic technology by specific physicians. For instance, brain tumors were tested in disproportionately high numbers, because of the number of patients seen and because our neuro-oncologists were early adopters of molecular testing. Finally, it might be of interest to know if GNA* abnormalities are early or late events. Future studies might consider evaluating paired primary and metastatic tumors.
In conclusion, GNA* aberrations were found across a range of malignancies, with ocular melanoma and appendiceal cancer having the strongest associations. These diseases are rare and have a dearth of effective therapies and clinical trials. Co-alterations in AURKA, SRC, CBL and LYN genes were often found in the presence of GNA* mutations. Development of drugs to target GNA* abnormalities and the alterations that frequently occur with them is needed.
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